LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
Overall LYEL gets a fundamental rating of 3 out of 10. We evaluated LYEL against 569 industry peers in the Biotechnology industry. While LYEL has a great health rating, there are worries on its profitability. LYEL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year LYEL has reported negative net income.
In the past year LYEL has reported a negative cash flow from operations.
LYEL had negative earnings in each of the past 5 years.
LYEL had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of LYEL (-32.94%) is better than 64.88% of its industry peers.
LYEL has a Return On Equity of -38.44%. This is in the better half of the industry: LYEL outperforms 73.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.94% | ||
| ROE | -38.44% | ||
| ROIC | N/A |
ROA(3y)-24.34%
ROA(5y)-23.76%
ROE(3y)-28.24%
ROE(5y)-28.98%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LYEL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LYEL has more shares outstanding
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.22, we must say that LYEL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LYEL (-1.22) is comparable to the rest of the industry.
LYEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.22 |
ROIC/WACCN/A
WACC10.43%
2.3 Liquidity
A Current Ratio of 13.43 indicates that LYEL has no problem at all paying its short term obligations.
LYEL has a better Current ratio (13.43) than 87.70% of its industry peers.
LYEL has a Quick Ratio of 13.43. This indicates that LYEL is financially healthy and has no problem in meeting its short term obligations.
LYEL has a better Quick ratio (13.43) than 87.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.43 | ||
| Quick Ratio | 13.43 |
3. Growth
3.1 Past
The earnings per share for LYEL have decreased strongly by -27.42% in the last year.
The Revenue for LYEL has decreased by -99.87% in the past year. This is quite bad
LYEL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -74.41% yearly.
EPS 1Y (TTM)-27.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y-74.41%
Revenue growth 5YN/A
Sales Q2Q%36%
3.2 Future
LYEL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.52% yearly.
Based on estimates for the next years, LYEL will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-9.52%
EPS Next 2Y-4.96%
EPS Next 3Y-1.52%
EPS Next 5YN/A
Revenue Next Year-99.61%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LYEL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LYEL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.96%
EPS Next 3Y-1.52%
5. Dividend
5.1 Amount
No dividends for LYEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LYELL IMMUNOPHARMA INC
NASDAQ:LYEL (11/22/2024, 8:00:00 PM)
After market: 0.9798 +0.03 (+3.14%)0.95
+0.03 (+3.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap265.26M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.94% | ||
| ROE | -38.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 13.43 | ||
| Quick Ratio | 13.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-27.42%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-9.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-99.87%
Revenue growth 3Y-74.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y